Amgen Inc. (NASDAQ:AMGN) Q2 2024 Results Conference Call August 6, 2024 4:30 PM ET
Company Participants
Justin Claeys - Vice President of Investor Relations
Bob Bradway - Chairman, CEO & President
Murdo Gordon - EVP, Global Commercial Operations
Vikram Karnani - EVP & President, Global Commercial Operations & Medical Affairs (Rare Disease)
Jay Bradner - EVP, Research and Development & Chief Scientific Officer
Peter Griffith - EVP & CFO
Conference Call Participants
Yaron Werber - TD Cowen
Salveen Richter - Goldman Sachs
Evan Seigerman - BMO Capital Markets
Mike Yee - Jefferies
Umer Raffat - Evercore ISI
Jay Olson - Oppenheimer
Mohit Bansal - Wells Fargo
Gregory Renza - RBC Capital Markets
Chris Raymond - Piper Sandler
Carter Gould - Barclays
Terence Flynn - Morgan Stanley
Chris Schott - JPMorgan
Kripa Devarakonda - Truist Securities
James Shin - Deutsche Bank
Gary Nachman - Raymond James
Operator
My name is Julianne, and I will be your conference facilitator today for Amgen's Second Quarter 2024 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at conclusion of the last speaker’s prepared remarks. In order to ensure that everyone has a chance to participate, we will like to request that you limit yourself to asking one question during the Q&A session. [Operator Instructions]
I would now like to introduce Justin Claeys, Vice President of Investor Relations. Mr. Claeys, you may now begin.
Justin Claeys
Thank you, Julianne. Good afternoon, everyone, and welcome to our second quarter 2024 earnings call. Bob Bradway will lead the call and be followed by a broader review of our performance by Murdo Gordon, Vikram Karnani, Jay Bradner and Peter Griffith.
Through the course of our discussion today, we will use non-GAAP financial measures to describe our performance and have provided appropriate reconciliations within the materials that accompany this call. We will also make some forward-looking statements, which are qualified by our safe harbor statement. And please note that actual results can vary materially.
Over to you, Bob.
Bob Bradway
Okay. Well, thank you, Justin, and let me thank all of you for joining the call today. We're especially grateful in light of all of the volatility in the markets that you would carve out the time to be with us. So thank you.
Through the first half of the year, our business is performing well, and we remain confident in our ability to deliver attractive long-term growth. We're achieving strong results the same way we always have, which is by providing innovative medicines to address challenging diseases.